AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Stock Short Interest Report for September

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the recipient of a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 1,407,198 shares, a decline of 49.1% from the September 15th total of 2,765,187 shares. Based on an average trading volume of 1,866,131 shares, the short-interest ratio is presently 0.8 days. Currently, 4.7% of the shares of the company are sold short.

AIM ImmunoTech Trading Down 3.5%

AIM traded down $0.01 on Wednesday, hitting $0.16. 310,817 shares of the stock traded hands, compared to its average volume of 11,720,511. The business has a fifty day moving average price of $0.22 and a two-hundred day moving average price of $0.34. The firm has a market capitalization of $4.99 million, a PE ratio of -0.05 and a beta of 1.27. AIM ImmunoTech has a 52 week low of $0.16 and a 52 week high of $2.88.

AIM ImmunoTech (NYSEAMERICAN:AIM) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.43) EPS for the quarter. The business had revenue of $0.03 million during the quarter. On average, equities research analysts forecast that AIM ImmunoTech will post -0.78 EPS for the current fiscal year.

About AIM ImmunoTech

AIM ImmunoTech Inc is a clinical-stage immuno-pharmaceutical company focused on developing therapies that activate and regulate the immune system. The company’s research programs target cancer, viral diseases and other conditions in which immune-system activity may play a role in disease progression or treatment response.

AIM’s principal investigational product is Ampligen (rintatolimod), a double-stranded RNA-based immune modulator designed to stimulate antiviral and antitumor immune responses.